BioNTech Gets Europe Priority Medicines Designation for Investigational Therapy Candidate
24 June 2022 - 01:50AM
Dow Jones News
By Denny Jacob
BioNTech SE said Thursday that the European Medicines Agency
granted priority medicines designation to BNT211, a potential
treatment for third- or later-line testicular germ cell tumors.
The product candidate, which combines two approaches in one
regimen, is currently being investigated in an ongoing Phase 1/2
study evaluating the safety and preliminary efficacy in heavily
pretreated patients with relapsed or refractory advanced solid
tumors, the company said.
The designation is based on positive preliminary Phase 1/2 data
from the ongoing study, BioNTech said. The results showed that the
treatment with CLDN6 CAR-T alone or in combination with CARVac, the
company's two combined products, was well tolerated and showed
positive signs of anti-tumor activity in testicular cancer patients
at the first evaluated dose levels, the company said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 23, 2022 11:35 ET (15:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2023 to Mar 2024